Janssen Reports Results of Darzalex (daratumumab) in P-III MAIA Study for Patients with Multiple Myeloma Ineligible for ASCT

 Janssen Reports Results of Darzalex (daratumumab) in P-III MAIA Study for Patients with Multiple Myeloma Ineligible for ASCT

Janssen Reports Results of Darzalex (daratumumab) in P-III MAIA Study for Patients with Multiple Myeloma Ineligible for ASCT

Shots:

  • The P-III MAIA study results involve assessing of Darzalex + lenalidomide + dexamethasone (Rd) vs Rd in 737 patients with newly diagnosed multiple myeloma ineligible for high-dose CT & ASCT aged 45-90 yrs.
  • The P-III MAIA study results: reduction in risk of disease progression (44%); ORR (92.9% vs 81.3%); CR (47.6% vs 24.9%); MRD-negative (24.2% vs 7.3%)
  • Darzalex is an Ab targeting CD38, inhibiting the tumor cell growth and has received FDA’s approval in Nov’15 as monothx. & in combination with Rd in Nov’16 for multiple myeloma prior treated with 3L & 1L therapy respectively

Click here to read full press release/ article | Ref: Janssen | Image: GMP news

Tuba Khan

Tuba Khan is an Editor and Digital Marketing expert at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in Lifesciences industry. She covers Pharma, Medical devices, Diagnostics and Digital health segment. Tuba also has an experience of digital and social media marketing and can run the campaign independently. She is also certified as a Digital marketer and social media marketer. She can be contacted on tuba@pharmashots.com

Related post